MARKER THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.29% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.47%.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 4.00%, a 100.00% increase year-over-year.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 2.00%, a 100.00% increase year-over-year.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 1.00%, a 0.00% change year-over-year.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.88%.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 100.00% increase from fiscal 2022.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.00%, a 100.00% increase from fiscal 2021.
- MARKER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.00%, a 0.00% change from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.29% 10-Q · filed 2026-08-14 | |||||
| 2025-12-31 | 3.88% 10-K · filed 2026-03-18 | |||||
| 2025-09-30 | 4.47% 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | 4.47% 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | 4.47% 10-Q · filed 2025-05-15 | |||||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | 4.00% 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 4.00% 10-Q · filed 2023-08-14 | |||||
| 2023-03-31 | 4.00% 10-Q · filed 2023-05-15 | |||||
| 2022-12-31 | 2.00% 10-K · filed 2024-03-26 | |||||
| 2022-09-30 | 2.00% 10-Q · filed 2022-11-10 | |||||
| 2022-06-30 | 2.00% 10-Q · filed 2022-08-11 | |||||
| 2022-03-31 | 2.00% 10-Q · filed 2022-05-13 | |||||
| 2021-12-31 | 1.00% 10-K · filed 2023-03-22 | |||||
| 2021-09-30 | 1.00% 10-Q · filed 2021-11-10 | |||||
| 2021-06-30 | 1.00% 10-Q · filed 2021-08-10 | |||||
| 2021-03-31 | 1.00% 10-Q · filed 2021-05-12 | |||||
| 2020-12-31 | 1.00% 10-K · filed 2022-03-17 | |||||
| 2020-09-30 | 1.00% 10-Q · filed 2020-11-09 | |||||
| 2020-06-30 | 1.00% 10-Q · filed 2020-08-10 | |||||
| 2020-03-31 | 1.00% 10-Q · filed 2020-05-11 | |||||
| 2019-12-31 | 2.00% 10-K · filed 2021-03-09 | |||||
| 2018-12-31 | 3.00% 10-K · filed 2020-03-12 | |||||
| 2017-12-31 | 2.00% 10-K · filed 2019-03-15 | |||||
| 2016-12-31 | 2.00% 10-K · filed 2018-03-23 | 1.60% 10-K · filed 2017-03-14 | ||||
| 2015-12-31 | 2.10% 10-K · filed 2017-03-14 | |||||
| 2015-03-06 | 1.70% 10-Q/A · filed 2016-04-14 | |||||
| 2015-02-10 | 1.52% 10-Q/A · filed 2016-04-14 | |||||
| 2014-09-30 | 0.05% 10-Q/A · filed 2016-04-14 | |||||
| 2014-06-30 | 0.05% 10-Q/A · filed 2016-04-14 | |||||
| 2014-03-31 | 0.05% 10-Q/A · filed 2016-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |